Sperogenix Therapeutics and Luca Healthcare announced a strategic partnership to develop digital therapeutics for Sperogenix’s pipeline of rare disease treatments and improve overall treatment benefits.

Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data.

Sperogenix will receive exclusive rights for development and commercialization of vamorolone for the treatment of Duchenne muscular dystrophy and any other rare disease.

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.

Mr. Yan Zhiyu was invited to attend the 9th China Rare Disease Summit held in Chengdu on 12 September and delivered a keynote speech on promoting China's participation in international multi-center clinical trials to accelerate orphan drugs access to China.

Sperogenix will have the exclusive right to develop, manufacture and commercialize ABSK021 in mainland China, Hong Kong SAR and Macao SAR for non-oncology rare neurological diseases indications.